Vericel price target raised to $42.40 from $40 at Ladenburg

Ladenburg analyst Jeffrey Cohen raised the firm’s price target on Vericel to $42.40 from $40 and keeps a Buy rating on the shares. The company’s Q4 preliminary results came in at the high end of the previously provided guidance, the analyst tells investors in a research note. While Vericel continues to prove dedicated to expanding sales growth, margin improvement and profitability are also expected to continue moving into 2024, says the firm.